Volume 2, Issue 2 (April 2023)
Health Science Monitor 2023, 2(2): 121-127 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sarrafan N, Pishva S S, Jafariheydarlou M, Irani Fam F, Seyyedi S A. Green tea relieves erosive, atrophic, and ulcerative lesions in patients with oral lichen planus: a pilot clinical trial study. Health Science Monitor 2023; 2 (2) :121-127
URL: http://hsm.umsu.ac.ir/article-1-106-en.html
URL: http://hsm.umsu.ac.ir/article-1-106-en.html
Negar Sarrafan 
, Seyyed Sajjad Pishva , Mohammad Jafariheydarlou , Fahimeh Irani Fam , Seyyed Amir Seyyedi *
, Seyyed Sajjad Pishva , Mohammad Jafariheydarlou , Fahimeh Irani Fam , Seyyed Amir Seyyedi *
Department of Oral and Maxillofacial School of Dentistry, Urmia University of Medical Science, Urmia, Iran
Abstract: (532 Views)
Background & Aims: Oral lichen planus (OLP) is a chronic inflammatory and autoimmune disease of stratified squamous epithelium. Numerous treatment approaches have been introduced for the treatment of OLP, but there is no substantial evidence to support the effectiveness of these methods. Green tea is a popular drink widely used to relief and treat inflammatory and autoimmune diseases. The present pilot study aimed to investigate the effect of green tea tablets on OLP.
Materials & Methods: In this pilot clinical trial study, we recruited 10 patients (48.1 ± 12.44 years old) with erosive and atrophic OLP from Western Azerbaijan, Urmia, in Iran. All patients received a green tea tablet (450 mg) daily for one month. The patients were monitored and followed up for pain severity scale with a visual analog scale (VAS), lesion size, and number of lesions. Finally, the collected data were examined using statistical software.
Results: The mean of VAS score before intervention was 4.1 ± 2.02, whereas it was 2.2 ± 2.25 at the end of the intervention. Statistical analysis indicated the decreased VAS score after 30 days of tablet consumption (p < 0.001). Moreover, lesion number and size were markedly decreased in patients after 30 days of tablet consumption. However, no complete recovery was observed in patients after 30 days.
Conclusion: Our study indicates that using green tea tablets could be an effective and complementary therapy for patients with erosive, inflammatory, and atrophic lesions. However, further studies are required to investigate green tea tablets efficiency in long-term usage.
Materials & Methods: In this pilot clinical trial study, we recruited 10 patients (48.1 ± 12.44 years old) with erosive and atrophic OLP from Western Azerbaijan, Urmia, in Iran. All patients received a green tea tablet (450 mg) daily for one month. The patients were monitored and followed up for pain severity scale with a visual analog scale (VAS), lesion size, and number of lesions. Finally, the collected data were examined using statistical software.
Results: The mean of VAS score before intervention was 4.1 ± 2.02, whereas it was 2.2 ± 2.25 at the end of the intervention. Statistical analysis indicated the decreased VAS score after 30 days of tablet consumption (p < 0.001). Moreover, lesion number and size were markedly decreased in patients after 30 days of tablet consumption. However, no complete recovery was observed in patients after 30 days.
Conclusion: Our study indicates that using green tea tablets could be an effective and complementary therapy for patients with erosive, inflammatory, and atrophic lesions. However, further studies are required to investigate green tea tablets efficiency in long-term usage.
Type of Study: Research |
Subject:
Health promotion and disease prevention
Received: 2023/01/7 | Accepted: 2023/02/1 | Published: 2023/04/21
Received: 2023/01/7 | Accepted: 2023/02/1 | Published: 2023/04/21
References
1. Ryan K, Hegarty AM, Hodgson T. Aetiology, diagnosis and treatment of oral lichen planus. Brit J Hosp Med. 2014;75(9):492-6. [DOI] [PMID]
2. Chainani-Wu N, Collins K, Silverman Jr S. Use of curcuminoids in a cohort of patients with oral lichen planus, an autoimmune disease. Phytomedicine. 2012;19(5):418-23. [DOI] [PMID]
3. Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. Sci World J. 2014;2014. [DOI] [PMID] [PMCID]
4. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007;49(2):89-106. [DOI] [PMID]
5. Krupaa RJ, Sankari SL, Masthan K, Rajesh E. Oral lichen planus: An overview. J Pharm Bioall Sci. 2015;7(Suppl 1):S158. [DOI] [PMID] [PMCID]
6. Mortazavi H, Safi Y, Baharvand M, Rahmani S. Diagnostic features of common oral ulcerative lesions: an updated decision tree. Int J Dent. 2016;2016. [DOI] [PMID] [PMCID]
7. Giuliani M, Troiano G, Cordaro M, Corsalini M, Gioco G, Lo Muzio L, et al. Rate of malignant transformation of oral lichen planus: A systematic review. Oral Dis. 2019;25(3):693-709. [DOI] [PMID]
8. Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):72-80. [DOI] [PMID]
9. Gupta S, Jawanda MK. Oral lichen planus: An update on etiology, pathogenesis, clinical presentation, diagnosis and management. Indian J Dermatol. 2015;60(3):222. [DOI] [PMID] [PMCID]
10. Wu Y, Zhou G, Zeng H, Xiong C-r, Lin M, Zhou H-m. A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2010;110(2):188-95. [DOI] [PMID]
11. Boorghani M, Gholizadeh N, Zenouz AT, Vatankhah M, Mehdipour M. Oral lichen planus: clinical features, etiology, treatment and management; a review of literature. J Dent Res Dent Clin Dent Prospect. 2010;4(1):3-9. [PMID] [PMCID]
12. Patil S, Khandelwal S, Sinha N, Kaswan S, Rahman F, Tipu S. Treatment modalities of oral lichen planus: an update. J Oral Diagn. 2016;1(1):1-8. [DOI]
13. Ghahremanlo A, Boroumand N, Ghazvini K, Hashemy SI. Herbal medicine in oral lichen planus. Phytother Res. 2019;33(2):288-93. [DOI] [PMID]
14. Winiarska-Mieczan A, Tomaszewska E, Jachimowicz K. Antioxidant, Anti-Inflammatory, and Immunomodulatory Properties of Tea-The Positive Impact of Tea Consumption on Patients with Autoimmune Diabetes. Nutrients. 2021;13(11):3972. [DOI] [PMID] [PMCID]
15. Wang S, Li Z, Ma Y, Liu Y, Lin CC, Li S, Zhan J, Ho CT. Immunomodulatory Effects of Green Tea Polyphenols. Molecules. 2021;26(12):3755. [DOI] [PMID] [PMCID]
16. Bagheri R, Rashidlamir A, Ashtary-Larky D, Wong A, Grubbs B, Motevalli MS, Baker JS, Laher I, Zouhal H. Effects of green tea extract supplementation and endurance training on irisin, pro-inflammatory cytokines, and adiponectin concentrations in overweight middle-aged men. Eur J Appl Physiol. 2020;120(4):915-23. [DOI] [PMID]
17. Ohishi T, Goto S, Monira P, Isemura M, Nakamura Y. Anti-inflammatory action of green tea. Antiinflamm Antiallergy Agents Med Chem. 2016;15(2):74-90. [DOI] [PMID]
18. Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus-a review. J Oral Pathol Med. 2010;39(10):729-34. [DOI] [PMID]
19. Sugerman P, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, Seymour GJ, Bigby M. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. 2002;13(4):350-65. [DOI] [PMID]
20. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(1):40-51. [DOI] [PMID]
21. Warnakulasuriya S, Johnson NW, Van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36(10):575-80. [DOI] [PMID]
22. Lavanya N, Jayanthi P, Rao UK, Ranganathan K. Oral lichen planus: An update on pathogenesis and treatment. J Oral Maxillofac Pathol. 2011;15(2):127. [DOI] [PMID] [PMCID]
23. Yoneyama S, Kawai K, Tsuno NH, Okaji Y, Asakage M, Tsuchiya T, Yamada J, Sunami E, Osada T, Kitayama J, Takahashi K. Epigallocatechin gallate affects human dendritic cell differentiation and maturation. J Allergy Clin Immunol. 2008;121(1):209-14. [DOI] [PMID]
24. Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, Sasaki S, Watanabe T, Takahashi K, Nagawa H. Epigallocatechin gallate induces apoptosis of monocytes. J Allergy Clin Immunol. 2005;115(1):186-91. [DOI] [PMID]
25. Wu D, Guo Z, Ren Z, Guo W, Meydani SN. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med. 2009;47(5):636-43. [DOI] [PMID]
26. Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther. 2010;12(2):1-9. [DOI] [PMID] [PMCID]
27. Fu Z, Zhen W, Yuskavage J, Liu D. Epigallocatechin gallate delays the onset of type 1 diabetes in spontaneous non-obese diabetic mice. Br J Nutr. 2011;105(8):1218-25. [DOI] [PMID] [PMCID]
28. Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol. 2009;58(10):519-37. [Google Scholar]
29. Wu D, Wang J, Pae M, Meydani SN. Green tea EGCG, T cells, and T cell-mediated autoimmune diseases. Mol Aspects Med. 2012;33(1):107-18. [DOI] [PMID]
30. Zhang J, Zhou G. Green tea consumption: an alternative approach to managing oral lichen planus. Inflamm Res. 2012;61(6):535-9. [DOI] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
